Published in Clin Pharmacol Ther on September 02, 1970
Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet (1971) 11.92
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
"Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet (1994) 3.33
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
Molecular virology and pathogenesis of hepatitis B. Lancet (1993) 3.27
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 2.56
Studies on the physiology of protein retention. J Physiol (1931) 2.30
Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol (2013) 2.11
Gastrointestinal Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Endoscopic and autopsy findings. Gastroenterology (1985) 1.90
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 1.85
Acute hepatitis C. Hepatology (2001) 1.82
T-cell responses and immunity to experimental infection with leishmania major. Annu Rev Immunol (1989) 1.68
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg (1997) 1.68
The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation (1995) 1.67
Autoimmune response to DNA, red blood cells, and thymocyte antigens in association with polyclonal antibody synthesis during experimental African trypanosomiasis. J Immunol (1979) 1.60
Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med (2001) 1.55
A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet (1995) 1.54
Hypomagnesemic hypocalcemia secondary to renal magnesium wasting. Ann Intern Med (1975) 1.52
Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut (2003) 1.51
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49
Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology (1999) 1.48
Are HCV-infected individuals candidates for hepatitis A vaccine? Lancet (1998) 1.46
Nitric oxide-induced mutations in the HPRT gene of human lymphoblastoid TK6 cells and in Salmonella typhimurium. Environ Mol Mutagen (2000) 1.46
Characterization of non-transferrin-bound iron clearance by rat liver. J Biol Chem (1986) 1.46
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology (1992) 1.41
Hepatitis C and liver transplantation. J Hepatol (2001) 1.40
REACTIONS OF MONKEYS TO EXPERIMENTALLY INDUCED INFLUENZA VIRUS A INFECTION : AN ANALYSIS OF THE RELATIVE ROLES OF HUMORAL AND CELLULAR IMMUNITY UNDER CONDITIONS OF OPTIMAL OR DEFICIENT NUTRITION. J Exp Med (1946) 1.39
Pruritus as a symptom of hepatitis C. J Am Acad Dermatol (1994) 1.39
Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer (1971) 1.37
Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells. Int Immunol (1991) 1.35
Recombinational repair is critical for survival of Escherichia coli exposed to nitric oxide. J Bacteriol (2001) 1.33
Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem (2000) 1.32
Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest (1985) 1.32
CENP-B binds a novel centromeric sequence in the Asian mouse Mus caroli. Mol Cell Biol (1995) 1.30
The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol (2001) 1.30
The influence of muscular work on protein metabolism. J Physiol (1932) 1.28
Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission. Ann Intern Med (1973) 1.27
Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest (1997) 1.24
The effect of prolonged hard muscular work on sulphur and nitrogen metabolism. J Physiol (1934) 1.24
Experiments on the nature of the labile rôle of sulphur in metabolism. J Physiol (1933) 1.23
Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology (1991) 1.21
A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. Am J Gastroenterol (2000) 1.21
Fate of antigen-binding cells in unresponsive and immune mice. J Exp Med (1973) 1.20
Recognition of protozoan parasite antigens by murine T lymphocytes. I. Induction of specific T lymphocyte-dependent proliferative response to Leishmania tropica. Eur J Immunol (1979) 1.20
Mouse centromere mapping using oligonucleotide probes that detect variants of the minor satellite. Chromosoma (1994) 1.20
Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology (1996) 1.19
Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol (1986) 1.19
When typical is atypical: mycobacterial infection mimicking cutaneous vasculitis. Rheumatology (Oxford) (2002) 1.18
Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology (1996) 1.17
Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology (2000) 1.17
Failure to detect hepatitis C virus genome in human secretions with the polymerase chain reaction. Hepatology (1991) 1.15
Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite, Leishmania major. Immunol Rev (1989) 1.12
Variants with reduced virulence derived from Leishmania major after mutagen treatment. Parasite Immunol (1987) 1.12
Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology (1998) 1.11
The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue-dependent pattern controlled by the Lsh and MHC loci. J Immunol (1996) 1.09
Leishmania major: differential regulation of the surface metalloprotease in amastigote and promastigote stages. Exp Parasitol (1992) 1.08
Autoimmunity and immune complex disease after neonatal induction of transplantation tolerance in mice. J Immunol (1983) 1.07
Aggravation of experimental cutaneous leishmaniasis in mice by administration of interleukin 3. Eur J Immunol (1988) 1.05
Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology (1998) 1.05
The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity. Eur J Immunol (1998) 1.05
In vitro and in vivo effects of interleukin 2 on the protozoan parasite leishmania. Eur J Immunol (1989) 1.04
Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr (1995) 1.04
Hepatitis C viral infection in liver transplant recipients. Hepatology (1992) 1.04
Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology (2001) 1.03
Hepatitis C virus: quantitation and distribution in liver. J Med Virol (1997) 1.03
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother (2002) 1.03
Mathematical model for the control of nosocomial norovirus. J Hosp Infect (2009) 1.03
Hepatitis C and liver transplantation. Gut (1999) 1.03
Interaction between cyclosporin and erythromycin in a kidney transplant patient. Eur J Clin Pharmacol (1986) 1.02
THE "VITAMIN M" FACTOR. Science (1943) 1.02
Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia (1999) 1.01
Differential nucleolar staining affinity with a modified Papanicolaou staining procedure. Stain Technol (1981) 1.01
Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. Cancer (1983) 1.01
Induction of thymocytotoxic autoantibodies after injection of bacterial lipopolysaccharides in mice. Eur J Immunol (1979) 1.00
Biocide gene(s) and biocidal activity in different strains of Bacillus sphaericus. Expression of the gene(s) in E. coli maxicells. Mol Gen Genet (1984) 1.00
Cholestatic hepatitis C in liver allografts. Liver Transpl Surg (1998) 0.97
Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology (1996) 0.96
Institutional performance in application of the FAB classification of acute leukemia. The Southwest Oncology Group experience. Cancer (1985) 0.96
A variational approach to the radiometric enhancement of digital imagery. IEEE Trans Image Process (1995) 0.96
Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet (1993) 0.96
Murine T lymphocyte specificity for African trypanosomes. II. Suppression of the T lymphocyte proliferative response to Trypanosoma brucei by systemic trypanosome infection. Clin Exp Immunol (1981) 0.95
Structural variation of the pseudoautosomal region between and within inbred mouse strains. Proc Natl Acad Sci U S A (1996) 0.95
The liver in generalized glycogen storage disease. Light microscopic observations. Am J Pathol (1966) 0.94
Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology (1993) 0.93
Frequency and cross-reactivity od cytolytic T lymphocyte precursors reacting against male alloantigens. J Immunol (1982) 0.93
Hepatitis C in patients undergoing liver transplantation. Ann Intern Med (1991) 0.92
Splenic injury following colonoscopy. Gastrointest Endosc (1990) 0.92
Specific Schistosoma mansoni rat T cell clones. I. Generation and functional analysis in vitro and in vivo. J Immunol (1985) 0.92
Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg (1996) 0.91
Phase II evaluation of bleomycin. A Southwest oncology Group study. Cancer (1976) 0.91
The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. J Clin Endocrinol Metab (2009) 0.91
Hepatitis C virus in the setting of transplantation. Semin Liver Dis (1995) 0.90
Narcolepsy in children. Sleep (1994) 0.90
[In vitro sensitivity of Yersinia pestis to some antibiotics and sulfonamides]. Med Trop (Mars) (1969) 0.89
Cyclophosphamide therapy in acute leukemia of childhood. Cooperative study conducted by members of Children's Cancer Cooperative Group A. Cancer (1966) 0.89